Citations

Mayo Clinic

Showing 10 of 108599 citations.

Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden
Botero, Juliana Perez , Majerus, Julie A. , Strege, Ann K., Johnson, Ryan D., Pruthi, Rajiv K. , Chen, Dong , Perez Botero, Juliana

American Journal of Clinical Pathology | February 15, 2017 | Volume: 147 | Issue: 6 | Pages: 604-610

10.1093/ajcp/aqx033 | PMID 28472350 Get It

AbstractObjectivesTo analyze the economic impact of testing for activated protein C resistance (APC-R) due to factor V Leiden (FVL) mutation with APC-R with reflexive FVL genotyping (algorithmic approach) or genotyping alone.MethodsOptumLabs Data Warehouse (OLDW) data were used to assess testing approaches. Insurance claims for APC-R and FVL in 2013 were compared with the Mayo Clinic database. Centers for Medicare & Medicaid Services diagnostic fee schedules were used to assign costs.ResultsOf 19.3 million OLDW-covered individuals, 74,242 (0.385%) received 75,608 tests: APC-R, 2,265 (2.9%); FVL genotyping, 70,619 (90.1%); and both APC-R and FVL, 2,724 (7.0%). In total, 1,317 tests were performed at Mayo Clinic: APC-R with reflex FVL (1,256; 95.4%) and FVL alone (61; 4.6%). Costs per evaluated individual and per total population (person/year) in OLDW and algorithmic approach were $83.77 vs $36.38 and $0.32 vs $0.14, respectively.ConclusionsThe cost-optimized algorithmic approach reduces health care costs.
Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry
Melloni, Chiara, Shrader, Peter, Carver, Joseph R. , Piccini, Jonathan P. , Thomas, Laine , Ansell, Jack , Go, Alan S. , Herling, Irving M., Yu, Anthony F. , Kowey, Peter R. , Fonarow, Gregg C. , Gersh, Bernard J. , Hylek, Elaine M. , Mahaffey, Kenneth W. , Peterson, Eric D.

European Heart Journal - Quality of Care and Clinical Outcomes | February 15, 2017 | Volume: 3 | Issue: 3 | Pages: 192-197

10.1093/ehjqcco/qcx004 | PMID 28838088 Get It

Abstract Aims The presence of cancer can complicate treatment choices for patients with atrial fibrillation (AF) increasing both the risk of thrombotic and bleeding events. Methods and results Using data from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation, we aimed to characterize AF patients with cancer, to describe their management and to assess the association between cancer and cardiovascular (CV) outcomes. Among 9749 patients, 23.8% had history of cancer (57% solid malignancy, 1.3% leukaemia, 3.3% lymphoma, 40% other type, and 2.2% metastatic cancer). Patients with history of cancer were older, more likely to have CV disease, CV risk factors, and prior gastrointestinal bleeding. No difference in antiarrhythmic and antithrombotic therapy was observed between those with and without cancer. Patients with history of cancer had a significantly higher risk of death (7.8 vs. 4.9 deaths per 100 patient-years follow-up, P = 0.0003) mainly driven by non-CV death (4.2 vs. 2.4 per 100 patient-years follow-up; P = 0.0004) and higher risk of major bleeding (5.1 vs. 3.5 per 100 patient-years follow-up; P = 0.02) compared with non-cancer patients; no differences were observed in risks of strokes/non-central nervous system embolism (1.96 vs. 1.48, P = 0.74) and CV death (2.89 vs. 2.07, P = 0.35) between the two groups. Conclusion A history of cancer is common among AF patients with up to one in four patients having both. Antithrombotic therapy, rates of cerebrovascular accident, other thrombotic events and cardiac death were similar in AF patients with or without a history of cancer. Patients with cancer, however, were at higher risk of major bleeding and non-CV death.
Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel
Akers, Amy , Salman, Rustam Al‐Shahi , Awad, Issam A. , Dahlem, Kristen, Flemming, Kelly D. , Hart, Blaine L. , Kim, Helen , Jusué-Torres, Ignacio , Lee, Cornelia , Rigamonti, Daniele , Rebeiz, Tania , Tournier‐Lasserve, Elisabeth , Waggoner, Darrel, Whitehead, Kevin J. , Flemming, Kelly, Kondziolka, Douglas , Morrison, Leslie , Flemming, Kelly D , Kim, Helen , Jusue-Torres, Ignacio , Al-Shahi Salman, Rustam

Neurosurgery | February 15, 2017 | Volume: 80 | Issue: 5 | Pages: 665-680

10.1093/neuros/nyx091 | PMID 28387823 Get It

Abstract BACKGROUND: Despite many publications about cerebral cavernous malformations (CCMs), controversy remains regarding diagnostic and management strategies. OBJECTIVE: To develop guidelines for CCM management. METHODS: The Angioma Alliance (www.angioma.org), the patient support group in the United States advocating on behalf of patients and research in CCM, convened a multidisciplinary writing group comprising expert CCM clinicians to help summarize the existing literature related to the clinical care of CCM, focusing on 5 topics: (1) epidemiology and natural history, (2) genetic testing and counseling, (3) diagnostic criteria and radiology standards, (4) neurosurgical considerations, and (5) neurological considerations. The group reviewed literature, rated evidence, developed recommendations, and established consensus, controversies, and knowledge gaps according to a prespecified protocol. RESULTS: Of 1270 publications published between January 1, 1983 and September 31, 2014, we selected 98 based on methodological criteria, and identified 38 additional recent or relevant publications. Topic authors used these publications to summarize current knowledge and arrive at 23 consensus management recommendations, which we rated by class (size of effect) and level (estimate of certainty) according to the American Heart Association/American Stroke Association criteria. No recommendation was level A (because of the absence of randomized controlled trials), 11 (48%) were level B, and 12 (52%) were level C. Recommendations were class I in 8 (35%), class II in 10 (43%), and class III in 5 (22%). CONCLUSION: Current evidence supports recommendations for the management of CCM, but their generally low levels and classes mandate further research to better inform clinical practice and update these recommendations. The complete recommendations document, including the criteria for selecting reference citations, a more detailed justification of the respective recommendations, and a summary of controversies and knowledge gaps, was similarly peer reviewed and is available on line www.angioma.org/CCMGuidelines.
Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals
Tosun, Duygu , Landau, Susan , Aisen, Paul , Petersen, Ronald C. , Mintun, Mark A., Jagust, William, Weiner, Michael W. , Initiative, for the Alzheimer’s Disease Neuroimaging, Initiative, for the Alzheimer’s Disease Neuroimaging, Tosun, Duygu

Brain | February 15, 2017 | Volume: 140 | Issue: 5 | Pages: 1499-1512

10.1093/brain/awx046 | PMID 28334939 Get It

Preserved endothelial progenitor cell angiogenic activity in African American essential hypertensive patients
Eirin, Alfonso , Herrmann, Sandra M. , Saad, Ahmed , Juncos, Luis A. , Textor, Stephen C., Lerman, Lilach O. , Kim, Seo Rin , Herrmann, Sandra M S, Lerman, Amir , Herrmann, Sandra M , Eirin, Alfonso , Juncos, Luis A

Nephrology Dialysis Transplantation | February 15, 2017 | Volume: 33 | Issue: 3 | Pages: 392-401

10.1093/ndt/gfx032 | PMID 28402508 Get It

Diagnostic impact of the 2016 revised who criteria for polycythemia vera
Barbui, Tiziano , Thiele, Jüergen, Gisslinger, Heinz , Carobbio, Alessandra , Tefferi, Ayalew , Vannucchi, Alessandro M.

American Journal of Hematology | February 14, 2017 | Volume: 92 | Issue: 5 | Pages: 417-419

10.1002/ajh.24684 | PMID 28196400 Get It

A Population-Based Study of Sociodemographic and Geographic Variation in HPV Vaccination
Wilson, Patrick M. , Jacobson, Debra J., Agunwamba, Amenah A. , Breitkopf, Carmen Radecki , Sauver, Jennifer L. St. , Finney Rutten, Lila J, Radecki Breitkopf, Carmen, Jacobson, Robert M. , St Sauver, Jennifer L, Rutten, Lila J. Finney , St Sauver, Jennifer L

Cancer Epidemiology, Biomarkers & Prevention | February 14, 2017 | Volume: 26 | Issue: 4 | Pages: 533-540

10.1158/1055-9965.epi-16-0877 | PMID 28196849 Get It

Abstract Background: Human papillomavirus (HPV) vaccination rates in the United States remain low and lag behind other recommended adolescent vaccines. Studies evaluating the association of geographic and area-level characteristics with HPV vaccination rates provide a valuable resource for public health planning. Method: We used the Rochester Epidemiology Project data linkage system to ascertain HPV vaccination rates between 2010 and 2015 in a 7-county region of southern Minnesota. Geocoded individual patient data were spatially linked to socioeconomic data from the American Community Survey at the census block group level. Bayesian hierarchical logistic regression was used to model incident vaccination rates, adjusting for individual- and area-level sociodemographic characteristics, and geolocation. Geolocation was modeled as an approximated Gaussian field using a Stochastic Partial Differential Equations approach. All models were estimated using Integrated Nested Laplace Approximations. Results: In adjusted models, increasing age and female sex were associated with increased HPV vaccination. Lower socioeconomic status was associated with decreased rates of initiation [adjusted odds ratio (AOR); 95% confidence interval = 0.90 (0.86–0.95)], completion of the second dose [AOR = 0.88 (0.83–0.93)], and completion of the third dose [AOR = 0.85 (0.80–0.92)]. Geographic spatial analysis demonstrated increased odds of vaccination for the eastern region and in the greater Rochester metropolitan area, showing significant spatial variation not explained by individual level characteristics and ACS block group-level data. Conclusions: HPV vaccination rates varied geographically and by individual and geographically indexed sociodemographic characteristics. Impact: Identifying geographic regions with low HPV vaccination rates can help target clinical and community efforts to improve vaccination rates. Cancer Epidemiol Biomarkers Prev; 26(4); 533–40. ©2017 AACR. See all the articles in this CEBP Focus section, “Geospatial Approaches to Cancer Control and Population Sciences.”
Idiopathic Subglottic Stenosis: Long‐Term Outcomes of Open Surgical Techniques
Menapace, Deanna C., Modest, Mara C., Ekbom, Dale C. , Moore, Eric J. , Edell, Eric S. , Kasperbauer, Jan L.

Otolaryngology–Head and Neck Surgery | February 14, 2017 | Volume: 156 | Issue: 5 | Pages: 906-911

10.1177/0194599817691955 | PMID 28195821 Get It

ObjectivesIdiopathic subglottic stenosis (iSGS) is rare, and its cause remains elusive. Treatment options include empiric medical therapy and endoscopic or open surgery. We present our results for open surgical technique.Study DesignCase series with chart review (1978‐2015).SettingTertiary academic center.Subjects/MethodsThirty‐three patients (32 female; median age, 51 years) met inclusion criteria and underwent cricotracheal resection with thyrotracheal anastomosis, tracheal resection with primary anastomosis, or laryngotracheoplasty with rib grafting. Continuous variables were summarized using medians and ranges while categorical features are presented using frequency counts and percentages.ResultsSixteen patients (48%) underwent a single‐stage approach with immediate extubation or temporary intubation following surgery (median, 1 day; range, 1‐3 days). Seventeen patients (52%) underwent a double‐staged approach with a median time to decannulation of 35 days (range, 13‐100 days). Twenty‐four (73%) patients underwent a previous intervention. Median stay in the intensive care unit was 1 day (range, 0‐3 days), with a median hospital stay of 4 days (range, 2‐7 days). Recurrence requiring further surgical intervention was observed in 12 patients (36%). The median time to recurrence was 8 years over an average follow‐up of 9.7 years. The most common complaint following surgery was change in voice quality (fair to poor; n = 10; 30%).ConclusionsOpen surgery should be reserved for refractory cases of iSGS; cricotracheal resection with thyrotracheal anastomosis is the preferred open technique. Recurrence may occur after open treatment, highlighting the importance of long‐term follow‐up. Patients should be counseled about the potential for worsening voice quality with the open approach.
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes
Brito, Juan P. , Montori, Víctor M. , Davis, Andrew M. , Brito, Juan P

JAMA | February 14, 2017 | Volume: 317 | Issue: 6 | Pages: 635

10.1001/jama.2016.20563 | PMID 28196240 Get It